Janux Soars On Early Efficacy, Safety For ‘Masked’ T-Cell Engagers
Phase Ia Studies Show Low Rates Of CRS
Janux reported early clinical trial data for its lead asset JANX007 that may show differentiated efficacy in the crowded PSMA space and for an EGFR agent with lung and kidney tumor shrinkage.
